TIVORBEX (indomethacin) by R-Pharm US is cyclooxygenase inhibitors [moa]. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 4d ago
TIVORBEX is an oral capsule formulation of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for acute pain management in adults. The product leverages a proprietary formulation to enhance bioavailability compared to conventional indomethacin.
Product is at peak lifecycle stage with moderate competitive intensity (8/10), suggesting stable but not rapidly expanding team size focused on market maintenance.
Cyclooxygenase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Worked on TIVORBEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
TIVORBEX positions professionals in a mature, competitive pain management market where commercial skills—including market access, payer negotiation, and field execution—are critical. Career growth is limited by the product's peak lifecycle status and impending LOE; roles emphasize defensive market strategies and cost management rather than expansion.